Notch1 and Notch3 were reported to drive airway basal cell hyperplasia of human airway epithelial cells (9), whereas signaling has been shown to mediate cytokine-driven goblet cell insults are less well understood(8). Notch2 (Notch receptor 2) modulate cellular homeostasis and responses to environmental stimuli. In the adult airway epithelial cells in the developing airways, regulating signaling path play a crucial role in controlling the fate of airway epithelial cells in the developing airways, regulating stem/progenitor cell renewal and differentiation. In the adult lung, the mechanisms by which Notch signaling components modulate cellular homeostasis and responses to environmental insults are less well understood (8). Notch2 (Notch receptor 2) signaling has been shown to mediate cytokine-driven goblet cell hyperplasia of human airway epithelial cells (9), whereas Notch1 and Notch3 were reported to drive airway basal cell differentiation toward secretary cells (10). During airway epithelial differentiation, Notch3 can prime a pool of basal cells into club cells that can later undergo differentiation into goblet or ciliated cells through Notch1/Notch2 downstream signaling, for which Notch ligand Jag1 (Jagged1) and Jag2 availability is required (11, 12). Specifically, Jag1 has been implicated in human airway epithelial cell differentiation toward secretory cells (13), whereas Notch3 has been shown to regulate goblet cell hyperplasia in airway epithelial cells from patients with COPD in response to rhinovirus infection (11). Furthermore, a recent study showed higher expression of Notch3 expression, but lower expression of Notch1, in asthmatic airway epithelium compared with control epithelium (15). Inhibition of Notch3 blocked MUC5AC production upon in vitro differentiation (15). Although expression of Notch target genes was found to be similar in club cells from patients with asthma and control subjects (9, 10), recent single-cell sequencing data in bronchial brushings have shown that the Notch target gene signature is lost in goblet cells and mucous ciliated cells in asthma (16). Collectively, this reveals an intricate interplay between Notch signaling components, encompassing balanced expression and timing during airway epithelial differentiation.

Although Notch signaling has been shown to contribute to mucous cell differentiation under homeostatic conditions, its involvement in allergen-induced goblet cell metaplasia has not been studied. In this issue of the Journal, Carrer and colleagues (pp. 46–56) (8) describe novel prophylactic and therapeutic effects of antisense oligonucleotide (ASO) downregulation of Jag1 and Notch2 on goblet cell metaplasia in a house dust mite (HDM) mouse model of allergen-induced asthma. The authors show that the Notch target gene signature is lost in goblet cells which Notch ligand Jag1 (Jagged1) and Jag2 availability is required (11, 12). Specifically, Jag1 has been implicated in human airway epithelial cell differentiation toward secretory cells (13), whereas Notch3 has been shown to regulate goblet cell hyperplasia in airway epithelial cells from patients with COPD in response to rhinovirus infection (11). Furthermore, a recent study showed higher expression of Notch3 expression, but lower expression of Notch1, in asthmatic airway epithelium compared with control epithelium (15). Inhibition of Notch3 blocked MUC5AC production upon in vitro differentiation (15). Although expression of Notch target genes was found to be similar in club cells from patients with asthma and control subjects (9, 10), recent single-cell sequencing data in bronchial brushings have shown that the Notch target gene signature is lost in goblet cells and mucous ciliated cells in asthma (16). Collectively, this reveals an intricate interplay between Notch signaling components, encompassing balanced expression and timing during airway epithelial differentiation.

Asthma and chronic obstructive pulmonary disease (COPD) are both chronic inflammatory respiratory disorders with a worldwide increase in incidence. Chronic mucus hypersecretion is prevalent in both diseases (1, 2) and is associated with more severe symptoms and exacerbations in asthma (3) and lower quality of life, accelerated lung function decline, increased risk of exacerbations, and higher mortality in COPD (1). Within the airway epithelial layer, goblet cells are responsible for the secretion of the mucin proteins MUC5AC and MUC5B, the main constituents of mucus in the respiratory tract. Processes that contribute to chronic mucus hypersecretion are goblet cell metaplasia, excessive mucus production, and impaired mucociliary clearance. Goblet cell metaplasia and loss of columnar ciliated cells represent key features of the chronically remodeled airways in both asthma and COPD.

Environmental risk factors for asthma and COPD include allergens, viral and bacterial infections, cigarette smoke, and air pollutants, which encounter the airway epithelial lining of the respiratory tract and disturb cellular homeostasis. This leads to increased mucosal permeability and is associated with increased numbers of mucus-producing cells (4, 5). Moreover, disruption of epithelial barrier function may propagate chronic inflammation and airway remodeling (4, 6). Indeed, many of the susceptibility genes for asthma and COPD are expressed in the airway epithelium, highlighting the importance of events at the mucosal layer for the pathogenesis of both diseases (4, 6). Nevertheless, the precise molecular mechanisms that underlie abnormalities in the airway epithelium of asthma and COPD are yet to be elucidated.

The pseudostratified airway epithelial layer consists of various epithelial cell types, of which basal cells, secretory club cells, mucus-producing goblet cells, and columnar ciliated cells are the major cell types. Basal cells serve as progenitors that can differentiate into an intermediate state of secretory club cells, which differentiate subsequently into either mucus-secreting goblet cells or mucus-clearing ciliated cells (7). The Notch signaling pathway plays a crucial role in controlling the fate of airway epithelial cells in the developing airways, regulating stem/progenitor cell renewal and differentiation. In the adult lung, the mechanisms by which Notch signaling components modulate cellular homeostasis and responses to environmental insults are less well understood (8). Notch2 (Notch receptor 2) signaling has been shown to mediate cytokine-driven goblet cell hyperplasia of human airway epithelial cells (9), whereas Notch1 and Notch3 were reported to drive airway basal cell differentiation toward secretory cells (10). During airway epithelial differentiation, Notch3 can prime a pool of basal cells into club cells that can later undergo differentiation into goblet or ciliated cells through Notch1/Notch2 downstream signaling, for which Notch ligand Jag1 (Jagged1) and Jag2 availability is required (11, 12). Specifically, Jag1 has been implicated in human airway epithelial cell differentiation toward secretory cells (13), whereas Notch3 has been shown to regulate goblet cell hyperplasia in airway epithelial cells from patients with COPD in response to rhinovirus infection (11). Furthermore, a recent study showed higher expression of Notch3 expression, but lower expression of Notch1, in asthmatic airway epithelium compared with control epithelium (15). Inhibition of Notch3 blocked MUC5AC production upon in vitro differentiation (15). Although expression of Notch target genes was found to be similar in club cells from patients with asthma and control subjects (9, 10), recent single-cell sequencing data in bronchial brushings have shown that the Notch target gene signature is lost in goblet cells and mucous ciliated cells in asthma (16). Collectively, this reveals an intricate interplay between Notch signaling components, encompassing balanced expression and timing during airway epithelial differentiation.
epithelial layer as a driver of obstructive lung disease (4, 6). In addition to the role of epithelial barrier dysfunction in airway inflammation and remodeling, goblet cell hyperplasia and MUC5AC-mediated plugging may play a critical role in airway hyperresponsiveness, mechanically contributing to increased reactivity to methacholine (8). However, the ASOs Carrer and colleagues administered to suppress Jag1 in the epithelium could conceivably have lessened bronchoconstriction by affecting smooth muscle cells if the ASOs also entered smooth muscle cells, although they argue against this possibility on the basis of historical evidence that ASOs do not efficiently target smooth muscle (8).

Seemingly in contrast to the role of Notch2 in HDM-induced goblet cell hyperplasia, HDM exposure resulted in downregulation of Notch2, which was accompanied by a downregulation of Scgb1a1 (8). The authors explain this HDM-induced downregulation by a reduction in the fraction of club cells upon HDM exposure and argue that only a robust downregulation of Notch2, such as by ASO treatment, will serve to prevent goblet cell metaplasia. It will be of high relevance to further elucidate the role of Notch signaling in epithelial cell fate upon injury (e.g., by allergens such as HDM), including effects on epithelial-to-mesenchymal transition and changes of epithelial barrier function related to disrupted differentiation, which may play a key role in airway remodeling in obstructive lung disease. The authors show that Jag1/Notch2 signaling, but not Notch1 and Notch3, are critical in determining the fate of club cell differentiation, an effect that may be mediated by regulation of Spdef expression (8). However, it is unclear from their study whether Spdef is a specific target of Notch2 signaling or if it is also regulated by Notch 1 and Notch3. It is rather unexpected that the authors have not observed any effects with knockdown of Notch1 or Notch3, given the previously described the role of both receptors in differentiation of human basal airway epithelial cells to secretory cells in vitro (10). It will be imperative to confirm their findings in a human setting, using primary bronchial epithelial cells from healthy donors as well as from patients with asthma. This is of particular importance because there have been contradictory findings on the role of Notch receptors in humans and mice (9, 14, 15). Moreover, it will be important to repeat the experiment with lower concentrations of HDM, because 2 mg/ml may not reflect the real-life situation. In addition, investigating the mechanism of Foxj1 regulation by Notch2 would be of interest. Nevertheless, the findings of Carrer and colleagues suggest that airway epithelial Jag1/Notch2 signaling may be a novel therapeutic target in allergic asthma, as well as in other respiratory diseases associated with excessive mucus secretion. Blockade of this pathway may serve to promote ciliary differentiation at the expense of goblet cell metaplasia, restoring the normal composition of the mucociliary epithelium, thereby also improving lung function.

Author disclosures are available with the text of this article at www.atsjournals.org.
References

1. Burgel PR. Cough and sputum production in COPD patients: clinical phenotype or markers of disease activity? Int J Clin Pract 2013;67: 1218–1219.

2. de Marco R, Marcon A, Janvis D, Accordini S, Almar E, Bugiani M, et al.; European Community Respiratory Health Survey Therapy Group. Prognostic factors of asthma severity: a 9-year international prospective cohort study. J Allergy Clin Immunol 2006;117:1249–1256.

3. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010;363:2233–2247.

4. Aghapour M, Raee P, Moghaddam SJ, Hiemstra PS, Heijink IH. Airway epithelial barrier dysfunction in chronic obstructive pulmonary disease: role of cigarette smoke exposure. Am J Respir Cell Mol Biol 2018;58:157–169.

5. Heijink IH, Nawijn MC, Hackett TL. Airway epithelial barrier function regulates the pathogenesis of allergic asthma. Clin Exp Allergy 2014; 44:620–630.

6. Nawijn MC, Hackett TL, Postma DS, van Oosterhout AJ, Heijink IH. E-cadherin: gatekeeper of airway mucosa and allergic sensitization. Trends Immunol 2011;32:248–255.

7. Montoro DT, Haber AL, Bilton M, Vinarsky V, Lin B, Birkef SE, et al. A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 2018;560:319–324.

8. Carrer M, Crosby JR, Sun G, Zhao C, Damle SS, Kuntz SG, et al. Antisense oligonucleotides targeting Jagged 1 reduce house dust mite–induced goblet cell metaplasia in the adult murine lung. Am J Respir Cell Mol Biol 2020;63:46–56.

9. Danahay H, Pessotti AD, Coote J, Montgomery BE, Xia D, Wilson A, et al. Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung. Cell Rep 2015;10:239–252.

10. Gomi K, Arbelaez V, Crystal RG, Walters MS. Activation of NOTCH1 or NOTCH3 signaling skews human airway basal cell differentiation toward a secretory pathway. PLoS One 2015;10: e0116507.

11. Jing Y, Gimenes JA, Mishra R, Pham D, Comstock AT, Yu D, et al. NOTCH3 contributes to rhinovirus-induced goblet cell hyperplasia in COPD airway epithelial cells. Thorax 2019;74:18–32.

12. Mori M, Mahoney JE, Stupnikov MR, Paez-Cortez JR, Szymaniak AD, Varelas X, et al. Notch3-Jagged signaling controls the pool of undifferentiated airway progenitors. Development 2015;142: 258–267.

13. Gomi K, Staudt MR, Salit J, Kaner RJ, Heldrich J, Rogalski AM, et al. JAG1-mediated Notch signaling regulates secretory cell differentiation of the human airway epithelium. Stem Cell Rev Rep 2016;12:454–463.

14. Tsao PN, Wei SC, Wu MF, Huang MT, Lin HY, Lee MC, et al. Notch signaling prevents mucous metaplasia in mouse conducting airways during postnatal development. Development 2011;138: 3533–3543.

15. Reid AT, Nichol KS, Veerati PC, Mohimani F, Kicic A, Stick SM, et al. Blocking Notch3 signaling abolishes MUC5AC production in airway epithelial cells from asthmatics. Am J Respir Cell Mol Biol 2020;62: 513–523.

16. Vieira Braga FA, Kar G, Berg M, Carpai OA, Polanski K, Simon LM, et al. A cellular census of human lungs identifies novel cell states in health and in asthma. Nat Med 2019;25:1153–1163.